H F Swijgman

Publications (2)6.75 Total impact

• Article: Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. An integration of three studies.

  J F O'Hanlon, A Vermeeren, M M Uiterwijk, L M van Veggel, H F Swijgman
  [show abstract] [hide abstract]
  ABSTRACT: Effects of benzodiazepine (diazepam, lorazepam) and benzodiazepine-like anxiolytics (alpidem, suriclone) and a 5-HT-3 antagonist (ondansetron) on actual driving performance were measured in three double-blind, placebo-controlled studies. Subjects were healthy volunteers in two and anxious patients in the third. Treatments lasted for 8 days. Standardized testing occurred within the first full day and on the last day of treatment. No important differences existed between volunteers' and patients' baseline and/or placebo performances and both groups responded similarly to comparable drugs/doses. Benzodiazepine and benzodiazepine-like anxiolytics produced marked and pervasive driving impairment, which lasted throughout treatment; but ondansetron, none.
  Neuropsychobiology 02/1995; 31(2):81-8. · 2.67 Impact Factor
• Article: Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo.

  J G Ramaekers, H F Swijgman, J F O'Hanlon
  [show abstract] [hide abstract]
  ABSTRACT: The acute and sub-chronic effects of moclobemide and mianserin on driving and psychometric performance were compared to those of placebo in a double-blind, cross-over study involving 17 healthy volunteers. Mianserin, moclobemide and placebo were administered for 8 days. Subjects' performance was measured on days 1 and 8 of each treatment series; subjective sleep parameters, mood, and possible side-effects were recorded each treatment day on questionnaires or visual analog scales. Mianserin affected most of the performance measures, while moclobemide affected none; mianserin also impaired driving and tracking performance and decreased CFF. Whilst receiving mianserin, subjects reported depressed levels of alertness, calmness, and contentment; the quality of their sleep was unaffected, but its duration increased, together with feelings of drowsiness and fatigue during the day. No statistical interactions between the factors Drugs and (Treatment) Days were found, indicating that little pharmacological tolerance developed over time during mianserin treatment. Mianserin's sedative properties are held responsible for all performance and subjective effects of the drug. It is concluded that moclobemide 200 mg b.i.d. has no important sedative properties.
  Psychopharmacologia 02/1992; 106 Suppl:S62-7. · 4.08 Impact Factor